<p>Accuray（纳斯达克代码：ARAY - 获取免费报告）在周日发布给客户和投资者的研究报告中，被华尔街 Zen 的股票研究人员将评级从 “持有” 下调至 “卖出”。</p>
<p>其他股票研究分析师也对该股票发布了研究报告。BTIG Research 在 11 月 6 日的研究报告中将 Accuray 的目标价格从 5.00 美元下调至 4.00 美元，并对该股票给予了 “买入” 评级。Weiss Ratings 在 12 月 22 日的报告中重申了对 Accuray 的 “卖出（d-）” 评级。一位股票研究分析师给予该股票 “买入” 评级，另一位则给予了 “卖出” 评级。根据 MarketBeat 的数据，该股票目前的平均评级为 “持有”，共识目标价格为 4.00 美元。</p>
<p><strong>查看我们最新的 ARAY 股票分析</strong></p>
<h2>Accuray 股票表现</h2>
<p>ARAY 股票在周五开盘价为 0.83 美元。该股票的 50 日简单移动平均为 1.14 美元，200 日简单移动平均为 1.36 美元。Accuray 的 12 个月低点为 0.81 美元，12 个月高点为 2.95 美元。该公司的市值为 9354 万美元，市盈率为-5.16，贝塔值为 1.06。该公司的流动比率为 1.56，速动比率为 0.76，债务与股本比率为 2.06。</p>
<p>Accuray（纳斯达克代码：ARAY - 获取免费报告）最近在 11 月 5 日发布了季度财报。这家医疗设备提供商报告季度每股收益为（0.18 美元），低于分析师共识预期的（0.05 美元）13 美分。该季度的营业收入为 9394 万美元，而分析师预期为 9134 万美元。Accuray 的股本回报率为-34.06%，净利润率为-4.28%。作为一个整体，股票研究分析师预测 Accuray 在当前年度将发布 0.01 美元的每股收益。</p>
<h2>Accuray 的机构交易</h2>
<p>大型投资者最近增加或减少了在该公司的持股。俄亥俄州公共雇员退休系统在第三季度新购入了 Accuray 的股份，价值 35,000 美元。Tower Research Capital LLC TRC 在第二季度将其在 Accuray 的持股增加了 604.2%。Tower Research Capital LLC TRC 目前拥有 35,177 股该医疗设备提供商的股票，价值 48,000 美元，此前在该期间内又购买了 30,182 股。BNP Paribas Financial Markets 在第三季度将其在 Accuray 的持股增加了 32.4%。BNP Paribas Financial Markets 目前拥有 39,369 股该医疗设备提供商的股票，价值 66,000 美元，此前在上个季度又购买了 9,633 股。Teton Advisors LLC 在第三季度新购入了价值约 67,000 美元的 Accuray 股份。最后，R Squared Ltd 在第三季度将其在 Accuray 的持股增加了 94.0%。R Squared Ltd 目前拥有 40,550 股该医疗设备提供商的股票，价值 68,000 美元，此前在该期间内又购买了 19,648 股。当前 64.08% 的股票由机构投资者和对冲基金持有。</p>
<h2>关于 Accuray</h2>
<p>（获取免费报告）</p>
<p>Accuray Incorporated（纳斯达克代码：ARAY）是一家全球医疗设备公司，开发、制造和销售创新的放射治疗解决方案用于癌症治疗。该公司的旗舰产品包括 CyberKnife®系统，这是一种提供亚毫米精度的机器人放射外科平台，以及 TomoTherapy®系统，它将螺旋计算机断层扫描（CT）成像与强度调制放射治疗（IMRT）相结合。最近，Accuray 推出了 Radixact®系统，这是其 TomoTherapy 技术的先进版本，旨在提高治疗速度和临床工作流程。</p>
<p>Accuray 的产品系列使临床医生能够提供高度针对性的放射剂量，同时最大限度地减少对周围健康组织的暴露。</p>
<h2>推荐故事</h2>
<ul>
<li>五只我们更看好的股票比 Accuray 更好</li>
<li>华尔街股票挑选者评选 2026 年第一只股票</li>
<li>麦当劳的秘密</li>
<li>4200 美元的黄金不错……但这是大多数黄金爱好者所忽视的</li>
<li>特朗普 5000 亿美元的计划正在推动这些每月分红</li>
<li>100 万美元在退休后能维持多久？</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在 Accuray 吗？</h2>
<p>在你考虑 Accuray 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Accuray 并不在名单上。</p>
<p>虽然 Accuray 目前在分析师中获得了 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

精确射线公司

<p>华尔街禅将 Accuray（NASDAQ:ARAY）的评级从 “持有” 下调至 “卖出”。BTIG 研究也将 Accuray 的目标价格从 5.00 美元下调至 4.00 美元，维持 “买入” 评级。Accuray 的股票开盘价为 0.83 美元，12 个月的价格区间为 0.81 美元至 2.95 美元。该公司报告了季度亏损，未能达到分析师的预期。机构投资者已调整了对该公司的持股。Accuray 专注于癌症治疗的放射治疗解决方案，产品包括 CyberKnife®和 TomoTherapy®系统</p>

<p>Accuray (NASDAQ:ARAY - Get Free Report) was downgraded by equities researchers at Wall Street Zen from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research report issued to clients and investors on Sunday.</p>
<div class="lb-trans"><p>Accuray（纳斯达克代码：ARAY - 获取免费报告）在周日发布给客户和投资者的研究报告中，被华尔街 Zen 的股票研究人员将评级从 “持有” 下调至 “卖出”。</p>
</div><p>Other equities research analysts have also issued research reports about the stock. BTIG Research dropped their price objective on shares of Accuray from $5.00 to $4.00 and set a &#34;buy&#34; rating on the stock in a research note on Thursday, November 6th. Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Accuray in a report on Monday, December 22nd. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of &#34;Hold&#34; and a consensus target price of $4.00.</p>
<div class="lb-trans"><p>其他股票研究分析师也对该股票发布了研究报告。BTIG Research 在 11 月 6 日的研究报告中将 Accuray 的目标价格从 5.00 美元下调至 4.00 美元，并对该股票给予了 “买入” 评级。Weiss Ratings 在 12 月 22 日的报告中重申了对 Accuray 的 “卖出（d-）” 评级。一位股票研究分析师给予该股票 “买入” 评级，另一位则给予了 “卖出” 评级。根据 MarketBeat 的数据，该股票目前的平均评级为 “持有”，共识目标价格为 4.00 美元。</p>
</div><p><strong>View Our Latest Stock Analysis on ARAY</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 ARAY 股票分析</strong></p>
</div><h2>Accuray Stock Performance</h2>
<div class="lb-trans"><h2>Accuray 股票表现</h2>
</div><p>ARAY stock opened at $0.83 on Friday. The stock's 50 day simple moving average is $1.14 and its 200 day simple moving average is $1.36. Accuray has a 12-month low of $0.81 and a 12-month high of $2.95. The firm has a market cap of $93.54 million, a P/E ratio of -5.16 and a beta of 1.06. The company has a current ratio of 1.56, a quick ratio of 0.76 and a debt-to-equity ratio of 2.06.</p>
<div class="lb-trans"><p>ARAY 股票在周五开盘价为 0.83 美元。该股票的 50 日简单移动平均为 1.14 美元，200 日简单移动平均为 1.36 美元。Accuray 的 12 个月低点为 0.81 美元，12 个月高点为 2.95 美元。该公司的市值为 9354 万美元，市盈率为-5.16，贝塔值为 1.06。该公司的流动比率为 1.56，速动比率为 0.76，债务与股本比率为 2.06。</p>
</div><p>Accuray (NASDAQ:ARAY - Get Free Report) last released its quarterly earnings data on Wednesday, November 5th. The medical equipment provider reported ($0.18) EPS for the quarter, missing analysts' consensus estimates of ($0.05) by ($0.13). The business had revenue of $93.94 million during the quarter, compared to analyst estimates of $91.34 million. Accuray had a negative return on equity of 34.06% and a negative net margin of 4.28%. As a group, equities research analysts predict that Accuray will post 0.01 EPS for the current year.</p>
<div class="lb-trans"><p>Accuray（纳斯达克代码：ARAY - 获取免费报告）最近在 11 月 5 日发布了季度财报。这家医疗设备提供商报告季度每股收益为（0.18 美元），低于分析师共识预期的（0.05 美元）13 美分。该季度的营业收入为 9394 万美元，而分析师预期为 9134 万美元。Accuray 的股本回报率为-34.06%，净利润率为-4.28%。作为一个整体，股票研究分析师预测 Accuray 在当前年度将发布 0.01 美元的每股收益。</p>
</div><h2>Institutional Trading of Accuray</h2>
<div class="lb-trans"><h2>Accuray 的机构交易</h2>
</div><p>Large investors have recently added to or reduced their stakes in the business. Public Employees Retirement System of Ohio acquired a new position in Accuray during the 3rd quarter worth $35,000. Tower Research Capital LLC TRC lifted its holdings in Accuray by 604.2% in the second quarter. Tower Research Capital LLC TRC now owns 35,177 shares of the medical equipment provider's stock worth $48,000 after purchasing an additional 30,182 shares during the period. BNP Paribas Financial Markets grew its position in Accuray by 32.4% in the 3rd quarter. BNP Paribas Financial Markets now owns 39,369 shares of the medical equipment provider's stock valued at $66,000 after buying an additional 9,633 shares in the last quarter. Teton Advisors LLC bought a new position in Accuray in the 3rd quarter valued at about $67,000. Finally, R Squared Ltd increased its stake in Accuray by 94.0% during the 3rd quarter. R Squared Ltd now owns 40,550 shares of the medical equipment provider's stock valued at $68,000 after buying an additional 19,648 shares during the period. 64.08% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>大型投资者最近增加或减少了在该公司的持股。俄亥俄州公共雇员退休系统在第三季度新购入了 Accuray 的股份，价值 35,000 美元。Tower Research Capital LLC TRC 在第二季度将其在 Accuray 的持股增加了 604.2%。Tower Research Capital LLC TRC 目前拥有 35,177 股该医疗设备提供商的股票，价值 48,000 美元，此前在该期间内又购买了 30,182 股。BNP Paribas Financial Markets 在第三季度将其在 Accuray 的持股增加了 32.4%。BNP Paribas Financial Markets 目前拥有 39,369 股该医疗设备提供商的股票，价值 66,000 美元，此前在上个季度又购买了 9,633 股。Teton Advisors LLC 在第三季度新购入了价值约 67,000 美元的 Accuray 股份。最后，R Squared Ltd 在第三季度将其在 Accuray 的持股增加了 94.0%。R Squared Ltd 目前拥有 40,550 股该医疗设备提供商的股票，价值 68,000 美元，此前在该期间内又购买了 19,648 股。当前 64.08% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>About Accuray</h2>
<div class="lb-trans"><h2>关于 Accuray</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Accuray Incorporated NASDAQ: ARAY is a global medical device company that develops, manufactures and markets innovative radiation therapy solutions for the treatment of cancer. The company's flagship products include the CyberKnife® System, a robotic radiosurgery platform offering sub-millimeter precision, and the TomoTherapy® System, which combines helical computed tomography (CT) imaging with intensity-modulated radiation therapy (IMRT). More recently, Accuray introduced the Radixact® System, an advanced iteration of its TomoTherapy technology designed to enhance treatment speed and clinical workflow.</p>
<div class="lb-trans"><p>Accuray Incorporated（纳斯达克代码：ARAY）是一家全球医疗设备公司，开发、制造和销售创新的放射治疗解决方案用于癌症治疗。该公司的旗舰产品包括 CyberKnife®系统，这是一种提供亚毫米精度的机器人放射外科平台，以及 TomoTherapy®系统，它将螺旋计算机断层扫描（CT）成像与强度调制放射治疗（IMRT）相结合。最近，Accuray 推出了 Radixact®系统，这是其 TomoTherapy 技术的先进版本，旨在提高治疗速度和临床工作流程。</p>
</div><p>Accuray's suite of products enables clinicians to deliver highly targeted radiation doses while minimizing exposure to surrounding healthy tissue.</p>
<div class="lb-trans"><p>Accuray 的产品系列使临床医生能够提供高度针对性的放射剂量，同时最大限度地减少对周围健康组织的暴露。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Accuray</li>
<li>Wall Street Stockpicker Names #1 Stock of 2026</li>
<li>The McDonald's Secret</li>
<li>$4,200 gold is nice ... but here’s what most gold bugs are missing</li>
<li>Trump's $500B plan is fueling these monthly dividends</li>
<li>How Long Will $1M Last in Retirement?</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票比 Accuray 更好</li>
<li>华尔街股票挑选者评选 2026 年第一只股票</li>
<li>麦当劳的秘密</li>
<li>4200 美元的黄金不错……但这是大多数黄金爱好者所忽视的</li>
<li>特朗普 5000 亿美元的计划正在推动这些每月分红</li>
<li>100 万美元在退休后能维持多久？</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Accuray Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 Accuray 吗？</h2>
</div><p>Before you consider Accuray, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Accuray 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Accuray wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Accuray 并不在名单上。</p>
</div><p>While Accuray currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Accuray 目前在分析师中获得了 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

精确射线公司（纳斯达克代码：ARAY）的评级在华尔街 Zen 被下调至卖出